Related Experiment Videos
An autopsied case of interferon encephalopathy
Y Mitsuyama1, H Hashiguchi, T Murayama
1Department of Psychiatry, Miyazaki Medical College, Japan.
The Japanese Journal of Psychiatry and Neurology
|September 1, 1992
Summary
High-dose interferon-alpha (IFN-alpha) treatment for renal carcinoma can cause severe neurotoxicity, including organic brain syndrome and white matter lesions. Pre-existing conditions may increase susceptibility to these adverse effects.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Interferon-alpha (IFN-alpha) is used in cancer treatment.
- High-dose infusions are a common administration route.
- Neurotoxicity is a known potential side effect of IFN-alpha therapy.
Observation:
- A 78-year-old male with renal carcinoma received high-dose IFN-alpha for eight months.
- The patient developed organic brain syndrome, including memory dysfunction, slowed behavior, and confusion.
- Symptoms appeared eight months into treatment, coinciding with diffuse white matter lesions on MRI.
Findings:
- Neuropathologic examination revealed findings consistent with Binswanger's disease and Senile Dementia of Alzheimer Type (SDAT).
- The patient had pre-existing intracerebral arteriosclerosis and cerebral atrophy.
- These pre-existing neurologic abnormalities may have increased susceptibility to IFN-alpha neurotoxicity.
Implications:
- High-dose IFN-alpha therapy carries a risk of significant neurotoxicity, potentially mimicking or exacerbating neurodegenerative diseases.
- Patients with pre-existing cerebrovascular or atrophic changes may be at higher risk for severe IFN-alpha-induced neurological adverse events.
- Careful patient selection and monitoring are crucial when administering high-dose IFN-alpha, especially in elderly patients with potential neurological comorbidities.